[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100620157":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":10,"centralContacts":12,"locations":10,"responsibleParty":18,"collaborators":10,"id":20,"slug":21,"hasResults":22,"nctId":23,"briefTitle":24,"officialTitle":24,"acronym":25,"eligibilityCriteria":26,"healthyVolunteers":22,"sex":27,"minAge":28,"maxAge":29,"enrollmentInfo":30,"targetDuration":33,"studyType":34,"phases":10,"briefSummary":35,"conditions":36,"keywords":41,"overallStatus":48,"whyStopped":10,"lastUpdateSubmitDate":49,"lastUpdatePostDateStruct":50,"startDateStruct":53,"completionDateStruct":55,"leadSponsor":57,"locationsCount":10},{"fullName":5,"class":6},"Second Affiliated Hospital of Wenzhou Medical University","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":10},"Severe Infection ICU Cohort Adult patients",null,"Adult patients with severe infection admitted to the intensive care unit (ICU). All participants receive standard clinical care as determined by their treating physicians. No experimental interventions are assigned.",[13],{"name":14,"role":15,"phone":16,"phoneExt":10,"email":17},"Shengwei Jin, PhD","CONTACT","+86-15068468153","jinshengwei69@163.com",{"type":19,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100620157","mechanisms-of-prognostic-regulation-andprecision-phenotype-ldentification-in-severe-infections-driven-by-specializedpro-resolving-mediators-100620157",false,"NCT07353970","Mechanisms of Prognostic Regulation andPrecision Phenotype Ldentification in Severe Infections Driven by SpecializedPro-Resolving Mediators","MPR-PPI-SPMs","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Admission to the intensive care unit (ICU)\n* Diagnosis of severe infection or sepsis, as determined by the treating physician according to current clinical criteria\n* Ability to obtain blood samples as part of routine clinical care within 24-48 hours after ICU admission\n* Informed consent provided by the patient or legally authorized representative (when applicable)\n\nExclusion Criteria:\n\n* Known pregnancy\n* Known immunosuppressive disease (e.g., hematologic malignancy, advanced HIV infection)\n* Use of long-term immunosuppressive therapy or systemic corticosteroids prior to ICU admission\n* Pre-existing end-stage disease with expected survival \\\u003C 28 days (e.g., end-stage cancer receiving palliative care)\n* Enrollment in interventional clinical trials that may influence immune or inflammatory responses\n* Refusal of informed consent by the patient or legal representative\n* Patients in whom blood sampling or follow-up is not feasible (e.g., expected transfer, withdrawal of life-sustaining treatment within 24 hours)","ALL","18 Years","100 Years",{"count":31,"type":32},300,"ESTIMATED","28 Days","OBSERVATIONAL","This is a prospective observational study involving adult patients with severe infection who are admitted to the intensive care unit (ICU). Severe infection and sepsis are major causes of death worldwide. Many patients experience uncontrolled inflammation or immune suppression, but current tests are limited in identifying which patients are at highest risk.\n\nThis study focuses on specialized pro-resolving mediators (SPMs), a group of naturally occurring lipid molecules that help the body turn off inflammation and promote healing. Blood samples that are collected during routine clinical care will be used to measure levels of SPMs. No additional blood draws or experimental treatments will be performed.\n\nThe purpose of this study is to understand how SPM levels change over time in patients with severe infection and how these changes relate to organ function and outcomes such as survival. By combining SPM measurements with routine laboratory results, immune cell counts, and imaging findings, the study aims to identify different clinical phenotypes and to develop tools that may help doctors recognize high-risk patients earlier in the future.\n\nAll participants will receive standard medical care determined by their treating physicians. No experimental drugs or interventions are given as part of this study.",[37,38,39,40],"Sepsis","Severe Infection","Multiple Organ Dysfunction Syndrome","Critical Illness",[42,43,44,45,46,47],"Specialized pro-resolving mediators","SPM","Resolvin D1","Immune resolution","Inflammation resolution","Critical care","NOT_YET_RECRUITING","2026-01-19",{"date":51,"type":52},"2026-01-21","ACTUAL",{"date":54,"type":32},"2026-01-15",{"date":56,"type":32},"2028-01-16",{"name":5,"class":6}]